Absorption, metabolism and excretion of darexaban (YM150), a new direct factor Xa inhibitor in humans.

@article{Hashimoto2013AbsorptionMA,
  title={Absorption, metabolism and excretion of darexaban (YM150), a new direct factor Xa inhibitor in humans.},
  author={Tadashi Hashimoto and Katsuhiro Suzuki and Yukie Kihara and Takafumi Iwatsubo and Aiji Miyashita and Marten Heeringa and Hartmut Onkels and Dorien Groenendaal and Frank W. S. M. Verheggen and Sjoerd P van Marle and Takashi Usui},
  journal={Xenobiotica; the fate of foreign compounds in biological systems},
  year={2013},
  volume={43 6},
  pages={534-47}
}
1. The absorption, metabolism and excretion of darexaban (YM150), a novel oral direct factor Xa inhibitor, were investigated after a single oral administration of [(14)C]darexaban maleate at a dose of 60 mg in healthy male human subjects. 2. [(14)C]Darexaban was rapidly absorbed, with both blood and plasma concentrations peaking at approximately 0.75 h post-dose. Plasma concentrations of darexaban glucuronide (M1), the pharmacological activity of which is equipotent to darexaban in vitro, also… CONTINUE READING